EGFR Activating Mutation, Lung Adenocarcinoma
Conditions
Brief summary
The objective of this observational study is to explore the therapeutic trajectory of targeted therapy in lung adenocarcinoma patients with epidermal growth factor receptor (EGFR) mutations. The main objective is to identify potential biomarkers that can predict the efficacy of targeted therapy through plasma exosomes and to explore strategies to reverse drug resistance to targeted therapy. Biological specimens and medical imaging data will be collected from patients already receiving targeted therapy as a first-line treatment, and followed-up will be conducted to analyze prognosis based on different patterns.
Detailed description
The medical imaging data will be collected retrospectively and prospectively, and the blood samples and tumor tissues will be collected prospectively.
Interventions
OTHERobservational study
Efficacy of targeted therapy combined with or without chemotherapy as first-line therapy in patients with EGFR-mutated lung adenocarcinoma.
Sponsors
Yichang Central People's Hospital
Suizhou Hospital, Hubei University of Medicine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Pathological examination confirmed lung adenocarcinoma * No other type of tumor was present * Common sensitive EGFR (Ex19Del L858R or combined with other sites) mutations have been identified * Receive targeted therapy with or without chemotherapy as first-line treatment * ≥ 18 years and ≤80 years old
Exclusion criteria
* History of other malignant tumors * Irregular treatment or poor compliance * Incomplete clinical information or lost to follow-up
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival | A two-year period after starting treatment (Regular follow-up every three months after receiving targeted therapy combined with or without chemotherapy as first-line treatment) | The time of disease progression is evaluated according to the Response Evaluation Criteria in Solid Tumors, version 1.1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | A three-year period after starting treatment (Regular follow-up every six months after receiving targeted therapy combined with or without chemotherapy as first-line treatment) | The survival time after receiving targeted therapy combined with or without chemotherapy as first-line treatment |
Countries
China
Outcome results
None listed